Startups
Humabs BioMed, a Subsidiary of Vir Biotechnology Inc., is a leading Swiss antibody therapeutics company that discovers and develops superior monoclonal antibodies directly derived from individuals whose immune system has successfully responded to major diseases. The company currently focuses on infectious diseases, but also has selected antibodies against inflammatory diseases and cancer in the pipeline.
Overview
Location
Switzerland, Ticino, Carasso
Employees
11-50
Founded date
2004
Mentions in press and media 5
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 25, 2017 | Humabs BioMed acquired by Vir Biotechnology | |
| Jun 24, 2015 | Humabs Receives Milestone Payment from Novartis | |
| Apr 14, 2015 | Humabs BioMed Reports Clinical Milestone in MedImmune Partnership | |
| Aug 21, 2013 | Successful partnership between Humabs and the Institute for Research in Biomedicine |
Reviews 0
FAQ about HUMABS
When was HUMABS founded?
HUMABS was founded in 2004.
What has the press written about HUMABS?
Parsers VC has collected 5 articles mentioning HUMABS, among them “Humabs BioMed acquired by Vir Biotechnology” (Sep 25, 2017) and “Humabs Receives Milestone Payment from Novartis” (Jun 24, 2015).
Is HUMABS still active?
Yes, HUMABS is active; its latest activity on Parsers VC dates from Sep 25, 2017.